Skip to main content
  • Real-World Xarelto Data Show Stroke, Bleeding Risk Low

    In a real-world analysis involving more than 11,000 patients with atrial fibrillation from 47 countries, the risk for stroke and major bleeding in users of the direct oral anticoagulant Xarelto (rivaroxaban) was similar to or lower than that seen in the pivotal clinical trials, researchers report.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details